Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0322 | 0.0322 | 0.0322 | 0 | 0 | CS |
4 | 0 | 0 | 0.0322 | 0.0322 | 0.0322 | 0 | 0 | CS |
12 | 0 | 0 | 0.0322 | 0.0322 | 0.0322 | 0 | 0 | CS |
26 | 0 | 0 | 0.0322 | 0.0322 | 0.0322 | 0 | 0 | CS |
52 | 0 | 0 | 0.0322 | 0.0322 | 0.0322 | 0 | 0 | CS |
156 | -3.6678 | -99.1297297297 | 3.7 | 3.765 | 0.0233 | 853208 | 0.84336315 | CS |
260 | -1.1278 | -97.224137931 | 1.16 | 5.98 | 0.0233 | 1254813 | 2.04626239 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.